Member Info for Num4

Contradicts your "codes", lol
http://www.pennystockdream.com/Market-Maker-Signals

Displaying on the trades for those that believe it means anything.

Hi Thoth, I guess we can't have it all - or perhaps they missed us discovering that and posting it on the board. Will certainly keep the momentum going for next week. Sentiment has changed, as expected and the next few months are make or break for Sareum. They are still committing to preclinical completion within 5months, all these years of development entering a 5month end period - now is the time to hold and trust in our well researched judgement of Tim and John.
Once the tyks are gone, via license, our job is essentially done - nothing in the pipeline currently for Tim or John to work on, will they search the SKIL platform again or resurrect an oldie? VEGFR3 etc, or was the chairman's takeover comment a nod?
The Lupus potential alone here is groundbreaking, market starting to catch up with this and for once I really don't think anything is priced in at these levels.
Enjoy what will be a very long weekend

Also worth noting that Tim hasn't yet adjusted the timescale for trials, still saying this year, usually these overrun and he moves it to H1 2021. If he makes this timescale I will certainly be amazed.

I don't think this lupus news was the reason for the buys earlier this week, just good timing and thanks to Citizen who alerted our BOD, certainly shouldn't be the way but again, timing is more important - as all the lth know.
Next week may see the COVID update and that is the reason for the increased volume. We really can't get any more evidence that these TYK2s need to go to clinic asap.
If we can get above 1p before news drops on COVID that would be the best outcome for this week and totally unexpected.

+share swap

Synairgen is good for everyone as it creates even more liquidity in a sector which has many more eyes than 6months ago, probably the reason the price has went so high, as RMM pointed out this is only a very small study stopped early to shout about it, Sareum prefer the peer reviewed routes. But again, this is good as when Sareum drop their COVID RNS this week or next it's the next bagger for the COVID hype, but for us, COVID is down the list for value creation. Cash out by Xmas would be the preferred option. Back to 1p plus with 2weeks imo.

Evening all, been offline for a while but found some time to review the patent documents Fadec posted, some great disclosures in these. What I can't seem to locate though, is the data for SDC-1801, from what I've been reading and going back on I don't think this has been published, we know about SAR-20347, this is the reserve molecule for SDC-1801, and SDC-1802 which targets cancers is SAR-20351, now looking more at this molecule it is not so much a TYK2/JAK1, but more a TYK2/JAK2 on selectivity profile.
The profile for SDC-1802 was very much unexpected when you read the patent documents and it has a binding percent control value of 0.2% against tyk2. What I can't locate though is the selectivity profile and PC against kinase targets for SDC-1801. I think it is only because of the patent issues with SDC-1802 that this (new) information is available.
The SP is probably at the best value you will get here for the huge upside, you just have to look at the money going into tyk2 by the big pharmas to make this an easy 6month investment. Tim and John will deliver because SDC-1801 and SDC-1802 have already delivered.

I joined it straight away and requested a DDM as they call it, no response and now your saying they've removed that function... Plenty to come gents and like all the times before when they release something all of our complaints and replaced by praise. Then the cycle repeats if nothing for another few months.
Wonder what an average day in the office is like for them now, remember all the talk about inlicensing something, SKIL platform screening must have stopped, we used to get some new compounds now nothing else is happening except waiting for TYK2s to enter trials or license, and the quoted data report made comment that they wouldn't be split in any license deal, or unlikely to be split.
What we need is our financial background chairmen to give us some form of update on progress, are we going down a II route to licence after PI or are we back loading for a preclinical deal. These are the strategies we need to be informed of, what are we doing and what is the plan - the real plan.
Can we wait another year, of course we all can!

Sareum have joined a something called https://www.investormeetcompany.com/

Looks like the new way for investor presentations and updates.

Register so you don't miss out and you can DDM to request a meeting. Nicely played, but will they follow through with the meeting requests. I shall see.

Grant funding a matter of time for this combo. Nice one Bighow

Is one of the best from Tim. So many insights and confidence in dealing anytime with a hot target and the right molecule. The second mouse gets the cheese...
https://youtu.be/nOoN4TLLZsI

https://endpts.com/pfizers-doug-giordano-has-500m-and-some-advice-to-offer-a-certain-breed-of-breakthrough-biotech/

Hi ajithoth. Thanks, I'm trying to up my game on that as the audience is much larger than these boards, imo.

We should be seeing a journal publication this month for SDC-1802 vs solid tumours, I am expecting to see something about tumour of the Kidney as Sareum have updated their target indications to ccRCC. clear cell renal cell carcinoma (ccRCC)—the most common form of kidney cancer. I think the momentum will continue as we have only positive news on the way. Although last June we placed.
Tim has also committed to the lupus data being published by DoD, surely he wouldn't put that in the presentations if he really didn't know it would happen.
Grant announcement this month also imo.
GLA

"A critical literature review suggests that the severity of SARS-CoV-2 infection is associated with dysregulation of inflammatory immune responses, which in turn inhibits the development of protective immunity to the infection. Therefore, the use of therapeutics that modulate inflammation without compromising the adaptive immune response could be the most effective therapeutic strategy."

Tim's favourite night reading source.

https://www.jimmunol.org/content/early/2020/05/15/jimmunol.2000413

When a single product, BMS-986165, has estimated 2024 sales of $1.1Billion, this COVID delay is damaging for BMS but unbelievably beneficial for Sareum. Sareum will, imo, use the grant money to prove safety in humans via the COVID link, whatever upfront payment was previously discussed is now back under negotiation. Deal structures could also be adapted to include larger milestones on safety data. Our negotiating hand has certainly been improved with the forthcoming grant, we may have had our backs against the wall with the lack of milestone from Sierra.
Now we are looking at a different angle; Sierra milestone now more likely and safety data for our 100% owned SDC-1801 part-funded via a grant. The icing on the cake, an improved survival rate for ICU patients.

mcap for Sareum will realign in due course.


https://finance.yahoo.com/news/bristol-myers-analyst-says-big-154507631.html
https://www.evaluate.com/vantage/articles/news/snippets/pivotal-readouts-threatened-covid-19-represent-20bn-investment

http://www.sareum.com/discovery/tyk2jak1-covid19/

Website now updated, RNS in the post.
Credit to the "foot soldiers", you know who you are.

http://www.sareum.com/discovery/overview/

In September 2016, the Company entered into an exclusive license agreement with CRT Pioneer Fund LP (CPF) for worldwide rights, know-how and materials to develop SRA737, a small molecule inhibitor targeting Chk1, a promising therapeutic target to treat cancer. Pursuant to the agreement, the Company made a one-time upfront payment of $7.0 million to CPF in October 2016 and paid $2.0 million to CPF in January 2017 for the successful transfer of two ongoing Phase 1 clinical trials. Additional milestone payments of up to an aggregate of $319.5 million may become payable to CPF upon the achievement of certain developmental, regulatory and commercial milestones, including a milestone payment of $7.5 million upon the dosing of the first patient in the first Phase 1 trial of SRA737 in the United States, and a payment of $12.0 million upon the dosing of the first patient of a randomized Phase 2 trial of SRA737. In the event that the milestone payment for Phase 2 becomes due, but no milestone payment for Phase 1 has been paid, then the milestone payment for Phase 1 will become due and payable contemporaneously with the payment for the Phase 2 milestone for an aggregate payment of $19.5 million. These milestones will be accrued once they are considered probable of occurring. In addition, the Company is required to pay CPF, on a product-by-product and country-by-country basis, tiered high single-digit to low double-digit royalties on the net sales of any product successfully developed.